184 reports of this reaction
1.5% of all DACARBAZINE reports
#20 most reported adverse reaction
ACUTE MYELOID LEUKAEMIA is the #20 most commonly reported adverse reaction for DACARBAZINE, manufactured by Fresenius Kabi USA, LLC. There are 184 FDA adverse event reports linking DACARBAZINE to ACUTE MYELOID LEUKAEMIA. This represents approximately 1.5% of all 12,161 adverse event reports for this drug.
Patients taking DACARBAZINE who experience acute myeloid leukaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE MYELOID LEUKAEMIA is a less commonly reported adverse event for DACARBAZINE, but still significant enough to appear in the safety profile.
In addition to acute myeloid leukaemia, the following adverse reactions have been reported for DACARBAZINE:
The following drugs have also been linked to acute myeloid leukaemia in FDA adverse event reports:
ACUTE MYELOID LEUKAEMIA has been reported as an adverse event in 184 FDA reports for DACARBAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE MYELOID LEUKAEMIA accounts for approximately 1.5% of all adverse event reports for DACARBAZINE, making it a notable side effect.
If you experience acute myeloid leukaemia while taking DACARBAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.